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We have characterized the pharmacological profile of the nonpeptide tachykinin NK2 receptor
antagonist ibodutant (MEN15596) through radioligand binding and contractility assays in the human
colon smooth muscle. The antagonist affinity of ibodutant was evaluated through concentration-
dependent inhibition curves at the [125I]NKA specific binding by using membranes prepared from
human colon smooth muscle. In this assay the affinity of ibodutant (pKi 9.9) was compared to that of
other two selective NK2 receptor antagonists, nepadutant (pKi 8.4) and saredutant (pKi 9.2). The
antagonist potency of ibodutant was evaluated towards the [bAla8]NKA(4-10)-mediated contractions of
human colon smooth muscle strips. In this assay ibodutant (3, 10, 30 and 100 nM) induced a
concentration-dependent rightward shift of the [bAla8]NKA(4-10) concentration-response curves
without depressing the maximal contractile effect. The analysis of the curves yielded a Schild-plot
linear regression with a slope not different from unity (1.02), thus indicating a surmountable antagonist
behavior. The calculated apparent antagonist potency as pKB value was 9.1. No sex related differences
were observed in NK2 receptor pharmacology for [bAla8]NKA(4-10) or ibodutant in colonic strips
obtained from male or female patients. Reversibility experiments of tachykinin NK2 receptor blockade
indicated that the inhibition of the agonist-induced contractions in preparations pre-exposed to
ibodutant, and afterwards subjected to repeated washing cycles remained almost constant showing
no sign of recovery during the 3 h observation period. Overall, the present study indicates ibodutant as
a potent tachykinin NK2 receptor antagonist in the human colon tissue, also endowed with a persistent
duration of action.
& 2013 Elsevier B.V. All rights reserved.1. Introduction
Tachykinin receptors, namely NK1, NK2 and NK3, are seven
transmembrane class-A (rhodopsin-like) G-protein coupled
receptors, widely expressed in the central and peripheral mam-
mal tissues (Shimizu et al., 2008). In the mammalian intestine,
tachykinins play a role as excitatory transmitters that mediate the
ascending excitatory reflex and atropine-resistant peristalsis
(Bartho´ and Holzer, 1985; Costa et al., 1985; Maggi et al. 1994)
either directly on muscle cells or indirectly by activating intramural
neurons (Bartho´ and Holzer, 1985; Holzer and Holzer-Petsche,
1997a, b). In human intestine tachykinin-like immunoreactivity
originates primarily from intrinsic neurons but also from the
peripheral endings of capsaicin-sensitive afferent neurons (Holzer
and Holzer-Petsche, 1997a). In the human colon, the tachykinin
receptors mediating smooth muscle contraction belong, for thell rights reserved.
, Menarini Ricerche S.p.A.,
55 5680735;
P. Santicioli).most part, to the NK2 type (Maggi et al., 1993) although radi-
oligand binding studies (Warner et al., 1999) have revealed the
presence of a small population of NK1 receptors, whose functional
role remains to be elucidated.
In this view, tachykinin NK2 receptor antagonists are regarded
as possible candidates for counteracting altered smooth muscle
motility and visceral hypersensitivity present in pathological
conditions characterized by an inflammatory state and impaired
motility such as irritable bowel syndrome (IBS) (Lecci et al., 2004
for review), and represent potential innovative therapeutic drugs
(Lecci et al., 2006; Quartara et al., 2009).
We recently developed a new potent tachykinin NK2 receptor-
selective nonpeptide antagonist, ibodutant (previously named
MEN15596) that is presently undergoing Phase-IIb clinical trial
for treatment of diarrhea-predominant IBS. The pharmacological
outlines of ibodutant have indicated its high affinity and selectiv-
ity for the human tachykinin NK2 receptor over the NK1 and NK3
and subnanomolar antagonist potency in human, guinea-pig, and
minipig in vitro bioassays (Cialdai et al., 2006). Moreover, ibodu-
tant displays a long duration of action both in vivo and in vitro,
due to its bioavailability, metabolic resistance, and long residence
P. Santicioli et al. / European Journal of Pharmacology 702 (2013) 32–37 33time on the tachykinin NK2 receptor (Cialdai et al., 2006; Meini
et al., 2009).
Smooth muscle preparations of the human colon have been
previously used to characterize both the potency and affinity of
different tachykinin NK2 receptor antagonists (Giuliani et al.,
1991; Advenier et al., 1992; Warner et al., 1999; Patacchini
et al., 2000). Therefore, the present investigation was undertaken
to characterize the pharmacological properties of ibodutant at the
tachykinin NK2 receptor in the circular muscle of the human
colon. Radioligand binding experiments using iodinated
neurokinin-A (NKA) and smooth muscle membranes were per-
formed to assess ibodutant affinity in comparison to that of other
tachykinin NK2 receptor antagonists (nepadutant and saredutant,
formerly known as MEN11420 and SR48968; Catalioto et al.,
1998; Emonds-Alt et al., 1993). Smooth muscle contractility
experiments were performed to evaluate the ibodutant antago-
nist potency and the reversibility of receptor blockade towards
the responses produced by the tachykinin NK2 receptor selective
agonist [bAla8]NKA(4-10). Moreover, since some sex-related var-
iations in NK2 receptor pharmacology in human colon have been
described (Burcher et al., 2008) we assessed whether the response
to NK2 receptor agonist and antagonist differs, at some extent, in
colonic strips from male and female patients.2. Materials and methods
2.1. Patients and specimens
All the procedures used in the present study were approved by
the Ethics Committee of the Medical Faculty of Florence Uni-
versity. Written informed consent was obtained from all patients.
Segments of human colon, approximately 10 cm in length,
were taken from grossly normal margins of surgical resections
from 16 patients (7 males and 9 females, age range 47–84 years)
undergoing partial colectomy for adenocarcinoma. Most seg-
ments were taken from the descending colon (9) and some from
sigmoid (3), ascending (2) and transverse (2) colon.
Immediately after resection, colonic segments were placed in
ice-cold Ringer-lactate solution and quickly transported to the
laboratory. No patient received radio or chemotherapy before
intervention. All specimens appeared macroscopically normal,
with no signs of tumor or inflammation.
The tissue was transferred into fresh oxygenated (95% O2 and
5% CO2) ice-cold Krebs solution of the following composition
(mmol/l): NaCl 119; NaHCO3 25; KH2PO4 1.2; MgSO4 1.5; CaCl2
2.5; KCl 4.7 and glucose 11, cleaned from serosal fat, mucosal
layer and tenia coli leaving the smooth muscle bands. Part of this
muscle was weighed, frozen and stored in liquid nitrogen and
then used to prepare membranes for radioligand binding experi-
ments. The remainder part of the tissue was used for functional
studies by dissecting strips (3 mm wide by 10–15 mm long; 5–8
from each segment) of muscular tissue in the direction of circular
muscular fibers. All strips for functional studies were stored
overnight at 4 1C in oxygenated (95% O2 and 5% CO2) Krebs
solution.2.2. Chemicals
Ibodutant (MEN15596; 6-methyl-benzo[b]thiophene-2-carboxylic
acid [1-(2-phenyl-1R-{[1-(tetrahydropyran-4-yl)methyl-piperidin-
4-ylmethyl]-carbamoyl}-ethylcarbamoyl)-cyclopentyl]-amide, batch
L3/08) and nepadutant (MEN11420; (cyclo-{[Asn(b-DGlcNAc)-Asp–
Trp–Phe–Dpr–Leu]cyclo(2b-5b)}), batches L1/04 and L1/08) were
synthesized at Lusochimica (Menarini Group, Lomagna, Italy).Saredutant (SR48968; (S)-N-methyl-N[4-(4-acetylamino-4-phe-
nylpiperidino)-2-(3,4-dichlorophenyl)butyl]benzamide) and the
nonpeptide NK1 receptor antagonist SR140333 ([(S)1-{2-[3-(3,4-
dichlorophenyl)-1-(3-isopropoxyphenylacetyl)piperidin-3-yl]ethyl}
-4-phenyl-1-azoniabicyclo[2,2,2]octane chloride]) were a kind gift
of Sanofi Aventis (Montpellier, France); NKA and [bAla8]NKA(4-10)
were from EspiKem (Firenze, Italy); atropine sulfate, indomethacin
and nifedipine were from Sigma-Aldrich (Milano, Italy). [125I]NKA
(NEX252, specific activity 2200 Ci mmol1) was from PerkinElmer
(Boston, MA, U.S.A.).
All salts used were of analytical grade and purchased from
Merck (Darmstadt, Germany). All other materials were from
Sigma-Aldrich (Milano, Italy).
2.3. Membranes preparation
Crude membranes were prepared as described in Burcher et al.
(1986) and Warner et al. (1999) with minor modifications. All of
the following procedures were performed at 4 1C. Tissues were
thawed on ice and then placed in 15 volumes of 50 mM Tris
containing 120 mM NaCl and 5 mM KCl (pH 7.4). It was first
minced by using fine scissors and then homogenized by using a
homogenizer (Ultra-Turrax T25, IKA Labortechnik) set at 20,500
loads min1. The homogenate was centrifuged at 48,000 g for
20 min and the pellet was re-homogenized and re-suspended in
50 mM Tris HCl (pH 7.4) containing 10 mM EDTA and 300 mM KCl
for 1 h. After centrifugation as before, the membranes were
washed twice in 50 mM Tris HCl. Before the last centrifugation
the protein content was determined according to Bradford (1976).
The membranes were finally re-suspended in binding buffer.
2.4. Radioligand binding studies
The binding buffer was 50 mM Tris HCl (pH 7.4) containing
0.02% bovine serum albumin (BSA), 3 mM MnCl2, 100 mg/ml
bacitracin, 10 mg/ml chymostatin, 5 mg/ml leupeptin, and 2.5 mg/
ml thiorphan. Non-specific binding was defined as the amount of
radiolabelled ligand bound in the presence of unlabeled NKA
(1 mM). Preliminary experiments were performed to verify the
protein concentration to be used (about 70–100 mg/ml, final
concentration) and the time to reach the radioligand binding
steady state (60 min). Competing ligands (NKA, ibodutant,
saredutant and nepadutant) were tested in a wide range of
concentrations (1 pM–10 mM, and serial dilutions were performed
with binding buffer. [125I]NKA concentration was in the range
between 0.066 and 0.093 nM. Binding reaction (at room T) started
at the time of membranes addition (final volume of 500 ml) and
stopped 60 min later by rapid filtration through UniFilter-96
plates (Packard Instrument Company), pre-soaked overnight in
BSA 0.5%, and using a MicroMate 96 Cell Harvester (Packard
Instrument Company). The tubes and filters were then washed
five times with 0.5 ml aliquots of Tris buffer (50 mM, pH 7.4, 4 1C)
containing 3 mM MnCl2 and 0.02% BSA. Filters were dried and
soaked in Microscint 40 (50 ml/well, Packard Instrument Com-
pany), and bound radioactivity was counted by a TopCount
Microplate Scintillation Counter (Packard Instrument Company).
2.5. Functional studies
The strips (15–20 h after excision) were placed in 5-ml organ
baths filled with oxygenated Krebs solution at 37 1C and con-
nected to isometric force transducers (Ugo Basile, Varese, Italy)
under an initial tension of 20 mN. Mechanical activity was
amplified and digitally recorded by an Octal Bridge Amplifier
connected to PowerLab/8sp hardware system and analyzed using
the Chart 4.2 software (AD Instruments, Australia).
Fig. 1. Inhibition curves of NKA, ibodutant, saredutant and nepadutant at the
[125I]NKA specifically bound to the human tachykinin NK2 receptor expressed in
membranes of human colon circular smooth muscle. Each point represents the
mean7S.E.M of seven experiments, each one performed in duplicate. Six mem-
brane preparations were used, each one obtained with the tissue from different
donors.
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tors was evaluated against the selective NK2 receptor agonist
[bAla8]NKA(4-10) (Maggi et al. 1993) in the presence of atropine
(1 mM), indomethacin (3 mM) and the selective tachykinin NK1
receptor antagonist SR140333 (0.1 mM).
After 60 min stabilization period two reproducible responses
to 80 mM KCl were established at 45 min intervals to assess tissue
viability. After a further 45 min equilibration period, during
which the medium was renewed every 15 min, nifedipine
(0.3 mM) was added to the Krebs solution and there was left in
all subsequent experimental phases to eliminate spontaneous
activity (Maggi et al. 1989; Zagorodnyuk et al. 1994). After
30 min of incubation in the presence of nifedipine the prepara-
tions were challenged with 1 mM [bAla8]NKA(4-10) to evaluate
the contractile response of each preparation.
After a further 90 min equilibration period, concentration-
response curves to the tachykinin NK2 receptor selective agonist
[bAla8]NKA(4-10), were cumulatively constructed. In each experi-
ment one strip was pretreated with the vehicle (DMSO; 1–3 ml/ml)
and used to perform the control curve to [bAla8]NKA(4-10), while
the other strips, obtained from the same specimen, were pre-
treated with ibodutant (3, 10, 30 and 100 nM) added to the organ
bath 60 min before the concentration-response curve to
[bAla8]NKA(4-10). In each preparation only one cumulative
concentration-response curve to [bAla8]NKA(4-10) was carried
out and only one concentration of the antagonist was tested.
In a separate series of experiments the reversibility of tachy-
kinin NK2 receptors blockade produced by ibodutant was eval-
uated in the human colon preparations using the technique as
described by Patacchini et al. (2000) and by Meini et al. (2009).
These experiments were also performed in the presence of
atropine (1 mM), indomethacin (3 mM), SR140333 (0.1 mM) and
nifedipine (0.3 mM). After a stabilization period of 60 min, pre-
parations were exposed twice, every 30 min, at a submaximal
concentration (171 nM) of [bAla8]NKA(4-10), calculated from
control concentration response curve of the agonist, as the one
producing 90% of its maximal contractile effect. After further
30 min, ibodutant (10, 30, 100 and 300 nM) or the vehicle (DMSO,
1–3 ml/ml) were added to the bath solution and incubated for
60 min before the next challenge with the agonist (Time 0). After
the agonist had produced its maximum contractile effect, the
preparations were subjected to a washing protocol of the agonist
and the antagonist consisting of three washing periods lasting
10 s each every 10 min during which the volume of the organ
bath was renewed five times for each washing period (15 renew-
als in all). Thereafter the administration of the agonist was
repeated every 30 min in antagonist-free solution to measure
the reversibility of antagonist action for 180 min.
2.6. Data evaluation and statistical analysis
All data in the text or figures are expressed as mean7standard
error of the mean (S.E.M.) or 95% confidence limits (95% c.l.).
Data from radioligand binding experiments were fitted by
nonlinear regression using GraphPad Software Prism 4.02 to
determine the equilibrium dissociation constant (Kd) from homo-
logous competition experiments performed with NKA, and the
ligand concentration inhibiting the radioligand binding of the 50%
(IC50) from heterologous competition experiments (ibodutant,
saredutant and nepadutant). Kd values were calculated as
IC50—[radioligand]. Ki values were calculated from IC50 using the
Cheng-Prusoff equation (Ki¼ IC50/(1þ[radioligand]/Kd) according
to the used concentration and the obtained Kd value of the
radioligand (Cheng and Prusoff, 1973) in each experimental
section (using tissue from the same donor). For graphical pre-
sentation data obtained at each concentration of competingligand, were normalized as percentage of specific binding as
follows: [(bound-nonspecific)/specific]100.
Functional data were fitted by sigmoidal nonlinear regression
(Prism 4.02, GraphPad Software) to determine the agonist con-
centration producing the 50% (EC50) of the maximal response
from the concentration-response curves. Differences in the max-
imum contractile effects between controls and ibodutant-
pretreated preparations were evaluated by one-way Analysis of
Variance (ANOVA) and the Dunnett Multiple Comparison Test.
The antagonist potency of ibodutant was expressed in terms of
pKB estimated as the mean of the individual values obtained with
the Gaddum equation: pKB¼ log(CR1) log[B] were CR is the
concentration-ratio calculated from equieffective concentrations
of agonist (EC50) obtained in the presence and in the absence of
antagonist and B is the used antagonist concentration (Kenakin,
2006).
Competitive antagonism was checked by the Schild regression
analysis by plotting the estimates of log(CR1) against log[B] to
determine the slopes of linear regression: a plot with linear
regression line and slope not significantly different from unity was
considered as proof of competitive antagonism (Arunlakshana and
Schild, 1959).
In reversibility experiments of tachykinin NK2 receptor block-
ade produced by antagonists performed in the human colon
preparation responses obtained in each strip at different time
were percentaged towards the basal response obtained in each
preparation (before antagonist treatment), and compared to those
obtained in control time-matched preparations. Data obtained
were analyzed by two-way analysis of variance (ANOVA) for
repeated measures followed by the Bonferroni post-test.3. Results
3.1. Radioligand binding inhibition experiments
The characterization of [125I]NKA binding sites was made by
means of NKA homologous competitive inhibition curves (Fig. 1).
NKA Kd value was 1.7770.20 nM (n¼7). All tested NK2 receptor
antagonists completely inhibited the [125I]NKA specific binding,
and the rank order of potency was ibodutant4saredutant4
nepadutant. The obtained pKi values were 9.970.14 (n¼7)
for ibodutant, 9.270.06 (n¼7) for saredutant and 8.470.15
(n¼7) for nepadutant (Table 1). The analysis of inhibition curves
Table 1
Comparison of ibodutant and tachykinin NK2 receptor antagonists affinity and
potency values detected in native and recombinant bioassays.
Binding affinity (pKi) Ibodutant Nepadutant Saredutant
Human colon smooth muscle 9.9 8.4 9.2
CHO/hNK2R 10.8
a 8.5b 9.8b
Antagonist potency (pKB)
Human colon smooth muscle 9.1 8.3c insurm.c
CHO/hNK2R 10.3–10.6
a 8.3a 9.8 insurm.a
insurm.¼ insurmountable.
Data are from the present study or from previous measurements performed in our
laboratories, as indicated.
The affinity (pKi) was evaluated in inhibiting the [
125I]NKA specific binding to
membranes prepared from smooth muscle of human colon or from CHO cells
stably expressing the human tachykinin NK2 receptor (CHO/hNK2R).
The antagonist potency (pKB) was evaluated in antagonizing contractile responses
induced by [bAla8]NKA(4-10) in the human colon smooth muscle or the inositol
phosphates accumulation induced by NKA in CHO/hNK2R.
a Meini et al., 2009.
b Renzetti et al., 1999.
c Patacchini et al., 2000.
Fig. 2. (A) Antagonism by ibodutant towards the contractile responses induced by
[bAla8]NKA(4-10) in the circular muscle strips of human colon. Concentration-
response curves for [bAla8]NKA(4-10) were constructed as described in Section 2
in the absence (control) and presence of the indicated concentrations of ibodutant
in the legend. Each value is the mean7S.E.M. of 10–13 experiments. (B) Schild
plot of agonist concentration ratios vs. ibodutant concentrations (Slope¼1.02, 95%
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model, whereas inhibition curves of the three antagonists did not
follow the law of mass action, and data were best fitted by a
variable slope regression with Hill slope values significantly less
than unity: 0.70 (95% c.l. 0.80 to 0.61) for ibodutant, 0.82
(95% c.l. 0.93 to 0.72) for saredutant, and 0.63 (95% c.l.
0.71 to 0.56) for nepadutant.c.l. 0.85–1.19; pKB¼9.170.05). Each value is the mean7S.E.M. of 10–13
experiments.3.2. Antagonism toward concentration-dependent contractions
produced by [bAla8]NKA(4-10)
In the presence of atropine (1 mM), indomethacin (3 mM),
SR140333 (0.1 mM) and nifedipine (0.3 mM) the selective NK2
receptor agonist [bAla8]NKA(4-10) produced slowly developing,
concentration-dependent, tonic contractions of the human iso-
lated circular colon: the Emax was 34.672.6 mN (n¼13). The EC50
value calculated from control (vehicle-treated) concentration-
response curves to [bAla8]NKA(4-10) was 12.4 nM (95% c.l.
11.113.9; n¼13).
Ibodutant (3, 10, 30 and 100 nM) was devoid of any effect on
the resting tension of the preparation whereas it concentration-
dependently and with high potency antagonized [bAla8]NKA
(4-10) -induced contractile responses producing a parallel rightward
shifts (Fig. 2A) of the agonist response curves without depressing the
agonist Emax (34.672.6; 33.272.9; 31.172.9; 33.374.9 and
37.071.7 mN in controls and in the presence of 3, 10, 30 and
100 nM of ibodutant, respectively). Schild plot analysis was consis-
tent with competitive antagonism (slope¼1.02, 95% c.l. 0.85–1.19)
and a pKB value of 9.170.05 was calculated (Fig. 2B).
No gender differences were seen in response to the NK2
receptor-agonist [bAla8]NKA(4-10) nor to the antagonist activity
of ibodutant. In particular the Emax to [bAla8]NKA(4-10) averaged
30.873.7 mN and 37.073.4 mN (n¼5 and n¼8, respectively,
n.s.) in strips from male and female, respectively. Likewise the
potency of [bAla8]NKA(4-10) averaged 15.4 nM (95% c.l. 12.6–18.9)
and 10.3 nM (95% c.l. 9.3–11.5) (n¼5 and n¼8, respectively, n.s.) in
strips from male and female, respectively.
With regard to ibodutant the analysis of its antagonist potency
toward [bAla8]NKA(4-10) yielded an apparent pKB value of
9.070.1 and 9.170.05 (n¼18 and n¼31, respectively, n.s.) in
colonic strips from male and female patients, respectively.3.3. Reversibility of functional tachykinin NK2 receptor blockade
Reversibility of functional tachykinin NK2 receptor blockade by
ibodutant was evaluated by measuring the capability of the
human colon muscle to recover the control contractile response
produced by a single submaximal concentration (171 nM) of
[bAla8]NKA(4-10) which induced about 90% of its maximum
contractile effect and amounted to 29.773.2 mN (n¼15).
After the incubation period of 60 min, ibodutant (10, 30, 100
and 300 nM) produced a significant concentration-dependent
inhibition of the contractile effect produced by [bAla8]NKA(4-10).
At this time (Time 0) the inhibitory effect induced by ibodutant was
2379, 55712, 7376 and 8478% at 10, 30, 100 and 300 nM,
respectively (Fig. 3). The inhibition remained constant for all
concentrations tested with no recovery of the subsequent responses
to the agonist obtained in drug-free medium for 180 min.4. Discussion
In this study the pharmacological characterization of the
tachykinin NK2 receptor antagonist ibodutant (MEN15596) is
presented in the circular smooth muscle of human colon, and
the high affinity and antagonist potency, besides the long dura-
tion of action of this antagonist, proved also in this tissue.
The determination of ibodutant affinity through radioligand
binding experiments indicate that this antagonist recognizes the
NKA binding sites present in the human colon with a significant
high affinity (pKi 9.9). In the same experiments the affinity of the
others tachykinin NK2 receptor antagonists, nepadutant and
saredutant, was evaluated as well. Present results indicate that
overall the rank order of affinity values for the three antagonists,
Fig. 3. Reversibility of tachykinin NK2 receptor blockade induced by ibodutant in
the isolated human colon. The values represent contractile responses to single
submaximal concentration (171 nM) of [bAla8]NKA(4-10) obtained in the absence
(control) or in the presence (time 0) of the indicated concentrations of ibodutant
administered 60 min before. Responses to the agonist were obtained every 30 min
during which three wash cycles were performed as described in Section 2. Data
are expressed as percentage of the basal response to [bAla8]NKA(4-10) obtained in
each preparation in the absence of the antagonist (or vehicle). Each value is the
mean7S.E.M of 3 experiments. * Significantly different toward the corresponding
control responses: po0.05.
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8.4), well matches with that previously obtained at the human
recombinant tachykinin NK2 receptor (ibodutant pKi 10.8, sare-
dutant pKi 9.8, nepadutant pKi 8.5; Meini et al., 2009; Renzetti
et al., 1999). The affinity of saredutant and nepadutant was
previously shown in the human colon also by Warner et al.
(1999) and the calculated pKi values are in a similar range
(saredutant 9.5 and nepadutant 9.1).
The antagonist potency of ibodutant estimated at the NK2
receptors of the human colon in the present study was similar
(pKB 9.170.05) to that found in human urinary bladder
(pKB¼9.2), guinea-pig colon (pKB¼9.3) and minipig urinary blad-
der (pKB¼8.8) NK2 receptor smooth muscle preparations (Cialdai
et al., 2006), but also in the inositol phosphates accumulation
induced by NKA in CHO cells expressing the human NK2 receptor
(pKB 10.3–10.6) (Meini et al., 2009).
The Schild analysis yielding to a slope (1.02) not significantly
different from unity clearly indicates the competitive antagonist
behavior of ibodutant in antagonizing the NK2 receptor-mediated
motor responses produced by the application of the selective NK2
receptor agonist [bAla8]NKA(4-10). In a previous study Burcher
et al. (2008) reported a significantly higher Bmax value for NK2
receptor in male as compared to female human colon, although
no differences in NK2 receptor mRNA were observed as well as no
difference in potency and maximal responses to NKA or [Lys5,
MeLeu9, Nle10]-NKA(4-10) were detected. Likewise, we failed to
detect any gender differences in the contractile response to
[bAla8]NKA(4-10) nor in the antagonist potency of ibodutant.
Overall the results of Burcher et al. (2008) and the present results
offer little ground to speculate for a gender-related differential
role of NK2 receptors in the genesis of symptoms of IBS.
We have previously shown (Cipriani et al., 2011) that ibodutant
prevents internalization of NK2 receptors induced by
[bAla8]NKA(4-10) in human colon. The receptor internalization is
unlikely to be relevant for present findings because: (a) the
techniques used to highlight receptor internalization requires a
prolonged exposition to the agonist at very low temperature
followed by a rapid heating, far different in terms of kinetics from
the present experimental conditions; (b) the protocol used in this
study enables reproducible responses to NK2 receptor agonists to
be performed at relatively short (30 min) time intervals thus
indicating that receptors internalization, if any, is negligible.
The kinetic profile of ibodutant was previously observed at
molecular level and its fast associating and slow dissociating
properties in the interaction with the human tachykinin NK2receptor assessed (Meini et al., 2009). In the current investigation,
the kinetic of ibodutant interaction at the NK2 receptor was
evaluated by using a functional experimental approach. Present
data indicate that ibodutant persistently binds to the human
tachykinin NK2 receptor expressed in the human colon smooth
muscle, as the inhibition of the motor response induced by
[bAla8]NKA(4-10) does not recover during the 3h observation
period in drug-free medium. These data obtained with ibodutant
resemble those previously observed with the tachykinin NK2
receptor antagonist saredutant in the same experimental model
(Patacchini et al., 2000). On the other hand, although the func-
tional receptor blockade exerted by ibodutant (present study) or
by saredutant (Patacchini et al., 2000) in the present assay appear
to be similar, analogs experiments performed in a cell system
(Meini et al., 2009) indicated that despite of their slow dissocia-
tion, both antagonists exerted a reversible functional blockade.
The different behavior obtained in the cell system and in the
smooth muscle tissue can be ascribed to the different experi-
mental parameters used, such as the concentrations of used
agonist and antagonist and the kinetics of the measured response.
On the other hand, despite the very slow dissociation property of
both ibodutant and saredutant they are endowed of a different
antagonist behavior. In particular although ibodutant slowly
reverts from the receptor compartment it exerts a surmountable
competitive antagonism type (present study, Meini et al., 2009),
whereas saredutant was reported to display an insurmountable
antagonism both in contractility smooth muscle (Patacchini et al.,
2000) and cell system assays (Meini et al., 2009).
NKA, via NK2 receptors, has been already documented to be a
major mediator of the non-adrenergic non-cholinergic (NANC)
excitatory imput to the circular muscle of human ileum (Maggi
et al., 1992) and colon (Cao et al., 2000; Aulı´ et al., 2008). It
appears therefore that the role of NKA as excitatory NANC enteric
neurotransmitter, as widely documented to exist in various
mammalian species (Holzer and Holzer-Petsche, 1997a,b), is
largely maintained in humans and there is abundant evidence
associating tachykinins with altered gastrointestinal motility,
secretion and visceral sensitivity (Lecci et al., 2004 for review)
thus making the field of tachykinins antagonists an appealing
target for the development of a new pharmacological treatment
of IBS.
The present findings, which document the potent and long
lasting NK2 receptor antagonist activity of ibodutant in human
colon, support the concept that this molecule is suitable candi-
date for therapeutic strategies aiming at a control of exaggerated
intestinal motility. Ibodutant is currently undergoing Phase II
clinical trial in IBS patient with predominant diarrhea.References
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